The global ‘dermatophytic onychomycosis treatment market‘ size is predicted to reach USD 6.63 billion by 2027, exhibiting a CAGR of 7.4% during the forecast period. The rising prevalence of diabetes and incidences of chronic nail fungus infection will lead to heavy demand for dermatophytic onychomycosis treatment, which, in turn, will foster the growth of the market, it is mentioned in a report, titled “Dermatophytic Onychomycosis Treatment Market Size, Share & COVID-19 Impact Analysis, By Product Type (Tablets and Nail Paints), By Route of Administration (Oral and Topical), By Type (Prescribed and Over-the-Counter (OTC)), By Distribution Channel (Hospitals & Clinics, Retail Pharmacies, and Online Channels), and Regional Forecast, 2020-2027” the market size stood at USD 3.74 billion in 2019.
Request a Sample Copy of the Research Report:
An Overview of the Impact of COVID-19 on this Market :
The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.
We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of corona virus outbreak across industries to help you prepare for the future.
Frequently Ask Question :
- What was the value of the global dermatophytic onychomycosis treatment market in 2019?
The value of the global dermatophytic onychomycosis treatment market was USD 3.74 billion in 2019.
- How much is the global market worth?
Fortune Business Insights says that the market is projected to reach USD 6.63 billion by 2027.
- What was the value of the market in North America in 2019?
The value of the market in North America was USD 1.65 billion in 2019.
Regional Analysis:
Increasing Prevalence of Onychomycosis to Aid Expansion in North America
The market size in North America stood at USD 1.65 billion in 2019. The growth in the region is attributed to rising cases of onychomycosis in the region. The growing R&D activities will further foster the growth of the market in the region. The increasing demand for Jublia will accelerate the growth of the market in the region. Europe is predicted to witness a high growth rate during the forecast period owing to the favorable health reimbursement policies in European countries such as Italy, Spain, and the U.K. The superior distribution of OTC drugs retail pharmacies such as Walgreens, and others will enable speedy expansion of the market in Europe. According to an article published in the Journal of the European Academy of Dermatology and Venereology, the prevalence of onychomycosis in Europe is 4.3%.
Asia Pacific is expected to rise tremendously in the forthcoming years due to the new product launches. The increasing prevalence of diabetes will spur opportunities for the market in the foreseeable future. The rising geriatric population will further improve the growth prospects of the market. In addition, the rising patient awareness and developing healthcare infrastructure in emerging economies will boost the market.
The report on the Dermatophytic Onychomycosis Treatment Market Reveals:
- Future insights into the industry
- An all-encompassing study of market size;
- In-detail data on all the segments
- Evidential information about competitors and prominent players
Market Driver:
Emergence of Topical Treatment Solutions to Augment Growth
The growing cases of liver damage in patients will lead to a high demand for the market in the near future. According to a survey conducted on dermatologists and podiatrists in the U.S. by Moberg Pharma AB in 2017, 7 out of 10 doctors avoid prescribing oral terbinafine owing to the risk of liver damage. The innovation and development of topical treatment solutions and oral anti-fungal drugsassociated with liver damage will subsequently enable speedy expansion of the market. The rising need for improved topical solutions will impel dermatologists and podiatrists to present new theories for drug enhancement, which, in turn, will augur well for the market. Moreover, the increasing adoption of nail lacquerswill consequently create new opportunities for the market during the forecast period. In addition, the increasing spending on R&D activities by major players will have a tremendous impact on the market in the foreseeable future.
For more information visit : https://www.fortunebusinessinsights.com/dermatophytic-onychomycosis-treatment-market-103310
Table of Content:
Report Introduction
Market Introduction
- Definition
- Scope Of The Study
- Research Objective
- Assumptions
- Limitations
Research Methodology
- Introduction
- Primary Research
- Secondary Research
- Market Size Estimation
Market Dynamics
- Drivers
- Restraints
- Opportunities
- Challenges
- Macroeconomic Indicators
- Technology Trends & Assessment
Market Factor Analysis
- Porter’s Five Forces Analysis
- Bargaining Power Of Suppliers
- Bargaining Power Of Buyers
- Threat Of New Entrants
- Threat Of Substitutes
- Intensity Of Rivalry
- Value Chain Analysis
- Investment Feasibility Analysis
- Pricing Analysis
Continue…
Key Development:
December 2019: Moberg Pharma, a Swedish pharmaceutical company announced that M0B-015, topical terbinafine under phase 3 clinical study has met the primary and secondary endpoint for the treatment of onychomycosis.
The Report Lists the Main Companies in the Dermatophytic Onychomycosis Treatment Market:
- Bausch Health Companies Inc.
- Pfizer Inc.
- Galderma
- GlaxoSmithKline plc
- Janssen Pharmaceuticals, Inc.
- Cipla Inc.
- Kaken pharmaceuticals Co., Ltd.
- Other Prominent Players
Have Any Query? Ask Our Experts:
Global Dermatophytic Onychomycosis Treatment Market Segmentation :
By Product Type
Tablets
Nail Paints
By Route of Administration
Oral
Topical
By Type
Prescribed
Over-the-Counter (OTC)
By Distribution Channel
Hospitals & Clinics
Retail Pharmacies
Online Channels
By Geography
North America (the U.S. and Canada)
Europe (U.K., Germany, France, Italy, Spain, Scandinavia, Russia, and Rest of Europe)
Asia-Pacific (Japan, China, India, Australia, New Zealand, Southeast Asia, andRest of Asia- Pacific)
Rest of World
Related Reports:
About Us:
Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights(TM) we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges
Contact Us:
Fortune Business Insights(TM) Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
